Objective  To explore the relevant factors affecting patients with liver metastasis of colorectal cancer, and to establish a nomogram prediction model to provide evidence for individualized diagnosis and treatment.

Methods  To retrospectively analyze the case information of colorectal cancer liver metastasis patients in the SEER database from January 2010 to December 2019. Lasso regression and Cox regression model were used to analyze independent risk factors affecting patient prognosis and establish the prediction nomogram model. The discrimination and consistency of the model were evaluated based on the receiver operating characteristic curve and its area under the curve (AUC), calibration curve and decision curve analysis (DCA).

Results A total of 5,121 patients with colorectal cancer liver metastases were included, comprising 3,631 cases in the modelling group and 1,490 cases in the validation group. Undifferentiated tumour grade [HR=4.29, 95%CI (2.74, 6.71)], positive neural infiltration tumour [HR=1.32, 95%CI (1.16, 1.49)], lymph node ratio (LNR)>0.6 [HR=1.70, 95%CI (1.28, 2.28)] were risk factors for patients with colorectal cancer liver metastases. Age>60 years old [HR=0.85, 95%CI (0.75, 0.95)] and surgery for metastatic lesions [HR=0.85, 95%CI (0.75, 0.96)] were protective factors for the prognosis of colorectal cancer patients with liver metastasis. A survival prediction model was established by nomogram. The AUC values for the modeling group and validation group were 0.722 and 0.732, respectively. The calibration curve approximates the ideal curve, and the DCA curve demonstrates that the model possesses good clinical validity.

Conclusion  This study is based on the SEER database to construct a survival prediction nomogram model, which has high discrimination, consistency, and clinical effectiveness, demonstrating the practicality of the prediction model in clinical practice.

1.Mahmoud NN. Colorectal cancer: preoperative evaluation and staging[J]. Surg Oncol Clin N Am, 2022, 31(2): 127-141. DOI: 10.1016/j.soc.2021.12.001.

RS. Colorectal cancer[J]. Clinical radiology, 2021, 76(12): 870. DOI: 10.1016/j.crad.2021.09.003.

3.Heinimann K. Hereditary cvolorectal cancer: clinics, diagnostics and management[J]. Ther Umsch, 2018, 75(10): 601-606. DOI: 10.1024/0040-5930/a001046.

4.Zhou E, Rifkin S. Colorectal cancer and diet: risk versus prevention, is diet an intervention?[J]. Gastroenterology clinics of North America, 2021, 50(1): 101-111. DOI: 10.1016/j.gtc.2020.10.012.

5.Szymańska-Chabowska A, Świątkowski F, Jankowska-Polańska B, et al. Nestin expression as a diagnostic and prognostic marker in colorectal cancer and other tumors[J]. Clin Med Insights Oncol, 2021, 15. DOI: 10.1177/11795549211038256.

6.Lin S, Wang Q, Zhu Y, et al. Establishment and validation of PTE prediction model in patients with cerebral contusion[J]. Sci Rep, 2022, 12(1): 20574. DOI: 10.1038/s41598-022-24824-z.

7.Wu H, Liu GJ, Zhang ZY, et al. Nomogram including chemotherapy response for prediction of intrahepatic progression-free survival in patients with colorectal liver metastasis through chemotherapy followed by radiofrequency ablation[J]. Int J Hyperthermia, 2021, 38(1): 633-639. DOI: 10.1080/02656736.2021.1912415.

8.Liu Z, Xu Y, Xu G, et al. Nomogram for predicting overall survival in colorectal cancer with distant metastasis[J]. BMC Gastroenterol, 2021, 21(1): 103. DOI: 10.1186/s12876-021-01692-x.

9.Liang JY, Wang DS, Lin HC, et al. A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma[J]. Int J Biol Sci, 2020, 16(13): 2430-2441. DOI: 10.7150/ijbs.45050.

10.Zeng J, Li K, Cao F, et al. Development and validation of survival prediction model for gastric adenocarcinoma patients using deep learning: a SEER-based study[J]. Front Oncol, 2023, 13: 1131859. DOI: 10.3389/fonc.2023.1131859.

11.康静, 蒋运兰, 李滔, 等. 结直肠癌患者术后并发肺部感染影响因素的Meta分析[J]. 数理医药学杂志, 2024, 37(10): 746-760. [Kang J, Jiang YL, Li T, et al. Influencing factors of postoperative pulmonary infection in patients with colorectal cancer: a Meta-analysis[J]. Journal of Mathematical Medicine, 2024, 37(10): 746-760.] DOI: 10.12173/j.issn.1004-4337.202406115.

12.Kim J, Lee HK. Potential role of the gut microbiome in colorectal cancer progression[J]. Front Immunol, 2021, 12: 807648. DOI: 10.3389/fimmu.2021.807648.

13.Song B, Wang L, Chen Y, et al. The significance of skip lymph node metastasis in colorectal cancer[J]. Anticancer Res, 2023, 43(9): 4169-4177. DOI: 10.21873/anticanres.16608.

14.Wang HW, Wang LJ, Jin KM, et al. Impact of age of onset on survival after hepatectomy for patients with colorectal cancer liver metastasis: a real-world single-center experience[J]. Curr Oncol, 2022, 29(11): 8456-8467. DOI: 10.3390/curroncol29110666.

15.Kim SE, Paik HY, Yoon H, et al. Sex- and gender-specific disparities in colorectal cancer risk[J]. World J Gastroenterol, 2015, 21(17): 5167-5175. DOI: 10.3748/wjg.v21.i17.5167.

16.Siegel RL, Jakubowski CD, Fedewa SA, et al. Colorectal cancer in the young: epidemiology, prevention, management[J]. Am Soc Clin Oncol Educ Book, 2020, 40: 1-14. DOI: 10.1200/EDBK_279901.

17.Mauri G, Sartore-Bianchi A, Russo AG, et al. Early-onset colorectal cancer in young individuals[J]. Mol Oncol, 2019, 13(2): 109-131. DOI: 10.1002/1878-0261.12417.

18.Patel SG, Boland CR. Colorectal cancer in persons under age 50: seeking causes and solutions[J]. Gastrointest Endosc Clin N Am, 2020, 30(3): 441-455. DOI: 10.1016/j.giec.2020.03.001.

19.Dong XF, Wang Y, Tang CH, et al. Upregulated WTAP expression in colorectal cancer correlates with tumor site and differentiation[J]. PloS one, 2022, 17(2): e0263749. DOI: 10.1371/journal.pone.0263749.

20.Saryglar RY, Lupatov AY, Yarygin KN. Colorectal cancer and tumor stromal cells have different effects on the differentiation and maturation of dendritic cells in vitro[J]. Bull Exp Biol Med, 2023, 174(4): 533-537. DOI: 10.1007/s10517-023-05743-z.

21.Wang S, Fan X, Zhu J, et al. The differentiation of colorectal cancer is closely relevant to m6A modification[J]. Biochem Biophys Res Commun, 2021, 546: 65-73. DOI: 10.1016/j.bbrc.2021.02.001.

22.Digiacomo N, Bolzacchini E, Veronesi G, et al. Neuroendocrine differentiation, microsatellite instability, and tumor-infiltrating lymphocytes in advanced colorectal cancer with BRAF mutation[J]. Clin Colorectal Cancer, 2019, 18(2): e251-e260. DOI: 10.1016/j.clcc.2018.12.003.

23.Wang Y, Wen Y, Wang J, et al. Clinicopathological differences of high fusobacterium nucleatum levels in colorectal cancer: a review and Meta-analysis[J]. Front Microbiol, 2022, 13: 945463. DOI: 10.3389/fmicb.2022.945463.

24.Zhao ZS, Qi YC, Wu JW, et al. Thromboelastography (TEG) parameters as potential predictors of malignancy and tumor progression in colorectal cancer[J]. World J Surg Oncol, 2023, 21(1): 354. DOI: 10.1186/s12957-023-03237-w.

25.Chakedis J, Schmidt CR. Surgical treatment of metastatic colorectal cancer[J]. Surg Oncol Clin N Am, 2018, 27(2): 377-399. DOI: 10.1016/j.soc.2017.11.010.

26.Bijelic L, Ramos I, Goeré D. The landmark series: surgical treatment of colorectal cancer peritoneal metastases[J]. Ann Surg Oncol, 2021, 28(8): 4140-4150. DOI: 10.1245/s10434-021-10049-3.

27.Salibasic M, Pusina S, Bicakcic E, et al. Colorectal cancer surgical treatment, our experience[J]. Med Arch, 2019, 73(6): 412-414. DOI: 10.5455/medarh.2019.73.412-414.

28.Zwager LW, Bastiaansen BAJ, Montazeri NSM, et al. Deep submucosal invasion is not an independent risk factor for lymph node metastasis in t1 colorectal cancer: a Meta-analysis[J]. Gastroenterology, 2022, 163(1): 174-189. DOI: 10.1053/j.gastro.2022.04.010.